Development of new screening system for Alzheimer disease, in vitro Aβ sink assay, to identify the dissociation of soluble Aβ from fibrils

Neurobiology of Disease

Volumn 22, Issue 3, 2006, Pages 487-495

  Sato, Naoyuki ^a   Okochi, Masayasu ^b   Taniyama, Yoshiaki ^a   Kurinami, Hitomi ^a   Shimamura, Munehisa ^a   Takeuchi, Daisuke ^a   Hamada, Hizuki ^a   Fukumori, Akio ^b   Kiyosue, Kazuyuki ^c   Taguchi, Takahisa ^c   Tanaka, Toshiyuki ^b   Miyasaka, Masayuki ^b   Takeda, Masatoshi ^b   Ogihara, Toshio ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

A ; Alzheimer disease; Amyloid; Memory; Ultrasound

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; MONOMER; OLIGOMER;

ALZHEIMER DISEASE; ARTICLE; DISSOCIATION; IRRADIATION; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN DETERMINATION; SCREENING TEST; SOLUBILITY; ULTRASOUND;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; BLOTTING, WESTERN; CHEMISTRY, ANALYTICAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PEPTIDE FRAGMENTS;

EID: 33744811200     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2005.12.010     Document Type: Article

References (50)

1. Alexandrov A.V., Demchuk A.M., Burgin W.S., Robinson D.J., and Grotta J.C. Ultrasound-enhanced thrombolysis for acute ischemic stroke: phase I. Findings of the CLOTBUST trial. J. Neuroimaging 14 (2004) 113-117
2. Alexandrov A.V., Wojner A.W., and Grotta J.C. CLOTBUST: design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke. J. Neuroimaging 14 (2004) 108-112
3. Ariani M., Fishbein M.C., Chae J.S., Sadeghi H., Michael A.D., Dubin S.B., and Siegel R.J. Dissolution of peripheral arterial thrombi by ultrasound. Circulation 84 (1991) 1680-1688
4. Blinc A., Francis C.W., Trudnowski J.L., and Carstensen E.L. Characterization of ultrasound-potentiated fibrinolysis in vitro. Blood 81 (1993) 2636-2643
5. Blinc A., Kennedy S.D., Bryant R.G., Marder V.J., and Francis C.W. Flow through clots determines the rate and pattern of fibrinolysis. Thromb. Haemost. 71 (1994) 230-235
6. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., St George Hyslop P., and Selkoe D.J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3 (1997) 67-72
7. Daffertshofer M., and Fatar M. Therapeutic ultrasound in ischemic stroke treatment: experimental evidence. Eur. J. Ultrasound 16 (2002) 121-130
8. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8850-8855
9. Esler W.P., Stimson E.R., Ghilardi J.R., Vinters H.V., Lee J.P., Mantyh P.W., and Maggio J.E. In vitro growth of Alzheimer's disease beta-amyloid plaques displays first-order kinetics. Biochemistry 35 (1996) 749-757
10. Fassbender K., Schmidt R., Schreiner A., Fatar M., Muhlhauser F., Daffertshofer M., and Hennerici M. Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. J. Neurol. Sci. 148 (1997) 101-105
11. Francis C.W., Onundarson P.T., Carstensen E.L., Blinc A., Meltzer R.S., Schwarz K., and Marder V.J. Enhancement of fibrinolysis in vitro by ultrasound. J. Clin. Invest. 90 (1992) 2063-2068
12. Glenner G.G., and Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120 (1984) 885-890
13. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 (1991) 704-706
14. Haga M., Shimura T., Nakamura T., Kato Y., and Suzuki Y. Effect of ultrasonic irradiation on the dissociation of antigen-antibody complexes. Application to homogeneous enzyme immunoassay. Chem. Pharm. Bull. (Tokyo) 35 (1987) 3822-3830
15. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., and Selkoe D.J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19 (1999) 8876-8884
16. Hasegawa K., Ono K., Yamada M., and Naiki H. Kinetic modeling and determination of reaction constants of Alzheimer's beta-amyloid fibril extension and dissociation using surface plasmon resonance. Biochemistry 41 (2002) 13489-13498
17. Hong A.S., Chae J.S., Dubin S.B., Lee S., Fishbein M.C., and Siegel R.J. Ultrasonic clot disruption: an in vitro study. Am. Heart J. 120 (1990) 418-422
18. Iwata N., Tsubuki S., Takaki Y., Watanabe K., Sekiguchi M., Hosoki E., Kawashima-Morishima M., Lee H.J., Hama E., Sekine-Aizawa Y., and Saido T.C. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6 (2000) 143-150
19. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., and Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13 (1994) 45-53
20. Jarrett J.T., Berger E.P., and Lansbury Jr. P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32 (1993) 4693-4697
21. Kheterpal I., Zhou S., Cook K.D., and Wetzel R. Abeta amyloid fibrils possess a core structure highly resistant to hydrogen exchange. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 13597-13601
22. Klein W.L. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41 (2002) 345-352
23. Kurochkin I.V., and Goto S. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 345 (1994) 33-37
24. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6448-6453
25. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., Yu C.E., Jondro P.D., Schmidt S.D., Wang K., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269 (1995) 973-977
26. Lomakin A., Chung D.S., Benedek G.B., Kirschner D.A., and Teplow D.B. On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1125-1129
27. Lombardo J.A., Stern E.A., McLellan M.E., Kajdasz S.T., Hickey G.A., Bacskai B.J., and Hyman B.T. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci. 23 (2003) 10879-10883
28. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., and Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155 (1999) 853-862
29. Matsuoka Y., Saito M., LaFrancois J., Gaynor K., Olm V., Wang L., Casey E., Lu Y., Shiratori C., Lemere C., and Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci. 23 (2003) 29-33
30. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., and Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (1999) 860-866
31. Miller M.W., Miller D.L., and Brayman A.A. A review of in vitro bioeffects of inertial ultrasonic cavitation from a mechanistic perspective. Ultrasound Med. Biol. 22 (1996) 1131-1154
32. Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B., and Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet. 1 (1992) 345-347
33. Naiki H., and Nakakuki K. First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro. Lab. Invest. 74 (1996) 374-383
34. Ono K., Hasegawa K., Naiki H., and Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 75 (2004) 742-750
35. Petkova A.T., Ishii Y., Balbach J.J., Antzutkin O.N., Leapman R.D., Delaglio F., and Tycko R. A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 16742-16747
36. Porter T.R., LeVeen R.F., Fox R., Kricsfeld A., and Xie F. Thrombolytic enhancement with perfluorocarbon-exposed sonicated dextrose albumin microbubbles. Am. Heart J. 132 (1996) 964-968
37. Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., Liang Y., Chi H., Lin C., Holman K., Tsuda T., et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376 (1995) 775-778
38. Rosenschein U., Bernstein J.J., DiSegni E., Kaplinsky E., Bernheim J., and Rozenzsajn L.A. Experimental ultrasonic angioplasty: disruption of atherosclerotic plaques and thrombi in vitro and arterial recanalization in vivo. J. Am. Coll. Cardiol. 15 (1990) 711-717
39. Rosenschein U., Furman V., Kerner E., Fabian I., Bernheim J., and Eshel Y. Ultrasound imaging-guided noninvasive ultrasound thrombolysis: preclinical results. Circulation 102 (2000) 238-245
40. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
41. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 (1995) 754-760
42. Solomon B., Koppel R., Frankel D., and Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4109-4112
43. Tamaoka A., Odaka A., Ishibashi Y., Usami M., Sahara N., Suzuki N., Nukina N., Mizusawa H., Shoji S., Kanazawa I., et al. APP717 missense mutation affects the ratio of amyloid beta protein species (A beta 1-42/43 and a beta 1-40) in familial Alzheimer's disease brain. J. Biol. Chem. 269 (1994) 32721-32724
44. Taniguchi S., Suzuki N., Masuda M., Hisanaga S.I., Iwatsubo T., Goedert M., and Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols and porphyrins. J. Biol. Chem. 280 (2005) 7614-7623
45. Van Nostrand W.E., and Porter M. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 38 (1999) 11570-11576
46. Vekrellis K., Ye Z., Qiu W.Q., Walsh D., Hartley D., Chesneau V., Rosner M.R., and Selkoe D.J. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20 (2000) 1657-1665
47. Walsh D.M., Lomakin A., Benedek G.B., Condron M.M., and Teplow D.B. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272 (1997) 22364-22372
48. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
49. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., and Cole G.M. Curcumin inhibits formation of Abeta oligomers and fibrils and binds plaques and reduces amyloid in vivo. J. Biol. Chem. 280 (2005) 5892-5901
50. Yoshioka K., Miki T., Katsuya T., Ogihara T., and Sakaki Y. The 717Val-Ile substitution in amyloid precursor protein is associated with familial Alzheimer's disease regardless of ethnic groups. Biochem. Biophys. Res. Commun. 178 (1991) 1141-1146